--- title: "Novo Nordisk Korea will lose about 100 billion to 175 billion won of Wegovy revenue over the next 12 months." description: "Hanmi's Eppe won approval on 7 October as Korea's first homegrown GLP-1 obesity drug and is due on sale by year end. Patients pay the full cost themselves. A rival priced at least 30% below Wegovy for" url: "https://bilby.ai/predictions/p/157/novo-nordisk-korea-will-lose-about-100-billion-to-175-billion-won-of-wegovy-reve" markdown: "https://bilby.ai/predictions/p/157/novo-nordisk-korea-will-lose-about-100-billion-to-175-billion-won-of-wegovy-reve.md" index: "https://bilby.ai/llms.txt" --- > For agents: Bilby answers questions about what governments do, from documents collected at source and checked by research analysts. To ask Bilby yourself, connect to its MCP server at https://pulse.bilby.ai/mcp (setup: https://docs.bilby.ai/developers/mcp-server). Every page on this site is also markdown: add .md to its address, or send Accept: text/markdown. https://bilby.ai/llms.txt lists them all. # Novo Nordisk Korea will lose about 100 billion to 175 billion won of Wegovy revenue over the next 12 months. - **Made:** 9 Oct 2026 - **By:** Owen Bae - **Market:** South Korea - **Outcome:** Unresolved Hanmi's Eppe won approval on 7 October as Korea's first homegrown GLP-1 obesity drug and is due on sale by year end. Patients pay the full cost themselves. A rival priced at least 30% below Wegovy forces a direct comparison. Wegovy is the weaker import because it holds about 15% of injectable sales against Eli Lily’s Mounjaro's 78%. Novo already cut Wegovy's starting dose by up to 42% before Mounjaro launched. It is likely to cut again and lose market share to Hanmi. The projected loss is four to seven times Novo Korea's 2025 operating profit of 24.2 billion won – while Lilly keeps its premium position. [Ask Bilby about this prediction](https://pulse.bilby.ai/?prompt=Novo%20Nordisk%20Korea%20will%20lose%20about%20100%20billion%20to%20175%20billion%20won%20of%20Wegovy%20revenue%20over%20the%20next%2012%20months.) ## Ask Bilby about it Carry the prediction into a question: what has changed since, who decides, and who is exposed. - [What has changed since it was made?](https://pulse.bilby.ai/?prompt=What%20has%20changed%20since%20Bilby%20predicted%20this%3F%20Novo%20Nordisk%20Korea%20will%20lose%20about%20100%20billion%20to%20175%20billion%20won%20of%20Wegovy%20revenue%20over%20the%20next%2012%20months.) - [Who decides whether it happens?](https://pulse.bilby.ai/?prompt=Who%20decides%20whether%20this%20happens%3F%20Novo%20Nordisk%20Korea%20will%20lose%20about%20100%20billion%20to%20175%20billion%20won%20of%20Wegovy%20revenue%20over%20the%20next%2012%20months.) - [Who gains and who loses if it does?](https://pulse.bilby.ai/?prompt=Who%20gains%20and%20who%20loses%20if%20this%20happens%3F%20Novo%20Nordisk%20Korea%20will%20lose%20about%20100%20billion%20to%20175%20billion%20won%20of%20Wegovy%20revenue%20over%20the%20next%2012%20months.) ## More from South Korea 27 predictions on South Korea so far, newest first. - 4 Nov 2026 · [Rhythm Pharmaceuticals is likely to exceed US$750 million in rare-obesity drug sales in 2027, more than double the annual sales pace implied by its third-quarter 2026 results.](https://bilby.ai/predictions/p/203/rhythm-pharmaceuticals-is-likely-to-exceed-us-750-million-in-rare-obesity-drug-s) · Unresolved - 27 Oct 2026 · [Washington’s South Korean advanced memory chipmaker anti-China restrictions will hit Samsung much harder than Beijing.](https://bilby.ai/predictions/p/188/washington-s-south-korean-advanced-memory-chipmaker-anti-china-restrictions-will) · Unresolved - 26 Oct 2026 · [South Korea’s steel market pushes back on China yet harder.](https://bilby.ai/predictions/p/187/south-korea-s-steel-market-pushes-back-on-china-yet-harder) · Unresolved [All 27 from South Korea](https://bilby.ai/predictions/log?tag=south-korea) · Marked true or false when each resolves ## See what we’re seeing next. New predictions in the Asia Daily Take, free every weekday, and in Bilby whenever you have a question. [Get the Asia Daily Take](https://bilby.ai/asia#asia-daily-take) · [Try Bilby](https://pulse.bilby.ai/sign-up)